Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The price of Pacific Biosciences of California Inc (NASDAQ: PACB) closed at $1.51 in the last session, up 7.86% from day before closing price of $1.4. In other words, the price has increased by $7.86 from its previous closing price. On the day, 8.05 million shares were traded. PACB stock price reached its highest trading level at $1.55 during the session, while it also had its lowest trading level at $1.41.
Ratios:
We take a closer look at PACB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.02 and its Current Ratio is at 6.92. In the meantime, Its Debt-to-Equity ratio is 11.37 whereas as Long-Term Debt/Eq ratio is at 11.36.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 18 ’25 when Van Oene Mark sold 26,836 shares for $1.31 per share. The transaction valued at 35,182 led to the insider holds 1,920,035 shares of the business.
MARK VAN OENE bought 26,836 shares of PACB for $35,174 on Aug 18 ’25. On May 19 ’25, another insider, Farmer Michele, who serves as the insider of the company, sold 5,195 shares for $1.00 each. As a result, the insider received 5,200 and left with 269,259 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PACB now has a Market Capitalization of 453559648 and an Enterprise Value of 841045632. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.91 while its Price-to-Book (P/B) ratio in mrq is 7.38. Its current Enterprise Value per Revenue stands at 5.388 whereas that against EBITDA is -3.726.
Stock Price History:
The Beta on a monthly basis for PACB is 2.24, which has changed by -0.025806427 over the last 52 weeks, in comparison to a change of 0.16845357 over the same period for the S&P500. Over the past 52 weeks, PACB has reached a high of $2.72, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is 15.39%, while the 200-Day Moving Average is calculated to be 10.13%.
Shares Statistics:
According to the various share statistics, PACB traded on average about 6.81M shares per day over the past 3-months and 6166890 shares per day over the past 10 days. A total of 300.35M shares are outstanding, with a floating share count of 264.44M. Insiders hold about 11.96% of the company’s shares, while institutions hold 56.84% stake in the company. Shares short for PACB as of 1757894400 were 45550788 with a Short Ratio of 6.69, compared to 1755216000 on 42168373. Therefore, it implies a Short% of Shares Outstanding of 45550788 and a Short% of Float of 17.26.
Earnings Estimates
A detailed examination of Pacific Biosciences of California Inc (PACB) is currently in progress, with 8.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.13, with high estimates of -$0.12 and low estimates of -$0.15.
Analysts are recommending an EPS of between -$0.52 and -$0.59 for the fiscal current year, implying an average EPS of -$0.56. EPS for the following year is -$0.5, with 8.0 analysts recommending between -$0.42 and -$0.55.
Revenue Estimates
According to 8 analysts,. The current quarter’s revenue is expected to be $40.25M. It ranges from a high estimate of $41.57M to a low estimate of $39.5M. As of. The current estimate, Pacific Biosciences of California Inc’s year-ago sales were $39.97MFor the next quarter, 8 analysts are estimating revenue of $42.86M. There is a high estimate of $44.77M for the next quarter, whereas the lowest estimate is $41M.
A total of 9 analysts have provided revenue estimates for PACB’s current fiscal year. The highest revenue estimate was $162.4M, while the lowest revenue estimate was $157.4M, resulting in an average revenue estimate of $160.22M. In the same quarter a year ago, actual revenue was $154.01MBased on 9 analysts’ estimates, the company’s revenue will be $185.76M in the next fiscal year. The high estimate is $201.6M and the low estimate is $177.7M.
